# An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen

> **NCT00344383** · PHASE2 · COMPLETED · sponsor: **McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Metrorrhagia

## Interventions

- **DRUG:** Norgestimate/Ethinyl Estradiol tablet

## Key facts

- **NCT ID:** NCT00344383
- **Lead sponsor:** McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2011-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344383, "An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00344383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*